Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Our objective was to determine the cost-effectiveness of Continuous Glucose Monitoring (CGM) technology with intensive insulin therapy compared to self-monitoring of blood glucose (SMBG) in adults with type 1 diabetes in the United States. METHODS: A Markov cohort analysis was used to model the long-term disease progression of 12 different diabetes disease states, using a cycle length of 1 year with a 33-year time horizon. The analysis uses a societal perspective to model a population with a 20-year history of diabetes with mean age of 40. Costs are expressed in $US 2007, effectiveness in quality-adjusted life years (QALYs). Parameter estimates and their ranges were derived from the literature. Utility estimates were drawn from the EQ-5D catalogue. Probabilities were derived from the Diabetes Control and Complications Trial (DCCT), the United Kingdom Prospective Diabetes Study (UKPDS), and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Costs and QALYs were discounted at 3% per year. Univariate and Multivariate probabilistic sensitivity analyses were conducted using 10,000 Monte Carlo simulations. RESULTS: Compared to SMBG, use of CGM with intensive insulin treatment resulted in an expected improvement in effectiveness of 0.52 QALYs, and an expected increase in cost of $23,552, resulting in an ICER of approximately $45,033/QALY. For a willingness-to-pay (WTP) of $100,000/QALY, CGM with intensive insulin therapy was cost-effective in 70% of the Monte Carlo simulations. CONCLUSIONS: CGM with intensive insulin therapy appears to be cost-effective relative to SMBG and other societal health interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F. L., Powe, N. R., & Golden, S. H. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00007 · Cited by 1,657
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Deiss, D., Bolinder, J., Riveline, J.-P., Battelino, T., Bosi, E., Tubiana-Rufi, N., Kerr, D., & Phillip, M. (2006) · Diabetes Care · doi:10.2337/dc06-1134 · Cited by 539
Screening for type 2 diabetes mellitus: a cost-effectiveness analysis
Hoerger, T. J., Harris, R., Hicks, K. A., Donahue, K., Sorensen, S., & Engelgau, M. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-9-200405040-00008 · Cited by 178 · cited 10×
“, inputs derived from the Diabetes Control and Complications Trial (DCCT), the United Kingdom Prospective Diabetes Study (UKPDS), and other literature sources) [14-17].”
BackgroundMethodInfluentialBailey, T. S., Zisser, H. C., & Garg, S. K. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2007.0205 · Cited by 159 · cited 1×
“While SMBG with intensive insulin therapy has been shown to be important for managing glucose levels [2,7-9], recent evidence has shown that continuous glucose monitoring (CGM) with intensive insulin therapy reduces overall A1c levels further, while holding hypoglycemic episodes constant [10-12].”
BackgroundJuvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2010) · Diabetes Care · doi:10.2337/dc09-1971 · Cited by 138
Cited by
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
“Similar results of the cost-effectiveness of rtCGM versus SMBG were reported using a larger, population-based model (40).”
ResultCurrent and Emerging Technology for Continuous Glucose Monitoring
Chen, C., Zhao, X.-L., Li, Z.-H., Zhu, Z.-G., Qian, S.-H., & Flewitt, A. (2017) · Sensors · doi:10.3390/s17010182 · Cited by 291
Bergenstal, R. M., Johnson, M., Passi, R., Bhargava, A., Young, N., Kruger, D. F., Bashan, E., Bisgaier, S. G., Isaman, D. J. M., & Hodish, I. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30368-x · Cited by 88
“Yet, due to its cost and complexity, the majority of the insulin users with insulin requiring type 2 diabetes will not likely utilize closed-loop delivery systems(13, 14).”
BackgroundThe Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes
Fonda, S. J., Graham, C., Munakata, J., Powers, J. M., Price, D., & Vigersky, R. A. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816628547 · Cited by 81
Addala, A., Maahs, D. M., Scheinker, D., Chertow, S., Leverenz, B., & Prahalad, P. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13082 · Cited by 83
Metadata
- Authors
- McQueen, R. B., Ellis, S. L., Campbell, J. D., Nair, K. V., & Sullivan, P. W.
- Venue
- Cost Effectiveness and Resource Allocation
- Published
- 2011
- Volume
- 9
- Issue
- 1
- Pages
- 13
- ISSN
- 1478-7547 (ISSN-L)
- OpenAlex
- W2110959201
- Cited by
- 74
- References
- 9
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. https://app.cochat.ai/papers/10.1186/1478-7547-9-13
- The paper
- McQueen, R. B., Ellis, S. L., Campbell, J. D., Nair, K. V., & Sullivan, P. W. (2011). Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. Cost Effectiveness and Resource Allocation. https://doi.org/10.1186/1478-7547-9-13
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.